Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Source:

Nursing2015

March 2006, Volume 36 Number 3 , p 30 - 30

Authors

Abstract

The FDA has approved an oral tablet, sorafenib tosylate (Nexavar), to slow the spread of advanced renal cell carcinoma. A multikinase inhibitor, Nexavar decreases tumor growth and angiogenesis.

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: